Transmitted HIV Drug Resistance — The Role of an Ultra-Sensitive Assay

In this prospective study, 20% of treatment-naive patients had minority drug-resistance mutations detected on an ultra-sensitive assay, but the presence of such mutations did not lead to worse outcomes.

Commercial genotyping assays can only detect mutations that are present in at least 20% of the viral population. In this prospective study, researchers used a more-sensitive assay to determine the prevalence of transmitted drug resistance and then evaluated the effects of that resistance on treatment outcome.

Levels of drug resistance were determined in 61 treatment-naive patients, using both a commercial genotyping kit (ViroSeq) and a more-sensitive multiplex-primer-extension assay (HIV-SNaPshot). The HIV-SNaPshot assay is able to detect the presence of nine mutations (6 associated with NRTI resistance and 3 with NNRTI resistance) at levels as low as 2% of the viral population. Testing was performed both on plasma and on proviral DNA from p…

Reviewing Authors

Jonathan Z. Li, MD

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Transmitted HIV Drug Resistance — The Role of an Ultra-Sensitive Assay

Topics

Reviewing Authors